124 related articles for article (PubMed ID: 9218083)
1. Zamifenacin (UK-76, 654) a potent gut M3 selective muscarinic antagonist, reduces colonic motor activity in patients with irritable bowel syndrome.
Houghton LA; Rogers J; Whorwell PJ; Campbell FC; Williams NS; Goka J
Aliment Pharmacol Ther; 1997 Jun; 11(3):561-8. PubMed ID: 9218083
[TBL] [Abstract][Full Text] [Related]
2. Pre-clinical and clinical pharmacology of selective muscarinic M3 receptor antagonists.
Wallis RM
Life Sci; 1995; 56(11-12):861-8. PubMed ID: 10188786
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the effects of a selective muscarinic receptor antagonist and hyoscine (scopolamine) on motion sickness, skin conductance and heart rate.
Golding JF; Stott JR
Br J Clin Pharmacol; 1997 Jun; 43(6):633-7. PubMed ID: 9205824
[TBL] [Abstract][Full Text] [Related]
4. Computerized planimetry in the objective assessment of the antispasmodic effect of Zamifenacin in double contrast barium enemas.
Hughes T; Wright AR; Owen JP; Keir MJ
Br J Radiol; 1996 Apr; 69(820):301-5. PubMed ID: 8665128
[TBL] [Abstract][Full Text] [Related]
5. Effects of oral cisapride on small bowel motility in irritable bowel syndrome.
Evans PR; Bak YT; Kellow JE
Aliment Pharmacol Ther; 1997 Oct; 11(5):837-44. PubMed ID: 9354190
[TBL] [Abstract][Full Text] [Related]
6. Management of irritable bowel syndrome: novel approaches to the pharmacology of gut motility.
Scarpignato C; Pelosini I
Can J Gastroenterol; 1999 Mar; 13 Suppl A():50A-65A. PubMed ID: 10202210
[TBL] [Abstract][Full Text] [Related]
7. Effect of alosetron on left colonic motility in non-constipated patients with irritable bowel syndrome and healthy volunteers.
Clemens CH; Samsom M; Van Berge Henegouwen GP; Fabri M; Smout AJ
Aliment Pharmacol Ther; 2002 May; 16(5):993-1002. PubMed ID: 11966509
[TBL] [Abstract][Full Text] [Related]
8. Irritable bowel syndrome: new pharmaceutical approaches to treatment.
Farthing MJ
Baillieres Best Pract Res Clin Gastroenterol; 1999 Oct; 13(3):461-71. PubMed ID: 10580922
[TBL] [Abstract][Full Text] [Related]
9. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers.
Houghton LA; Foster JM; Whorwell PJ
Aliment Pharmacol Ther; 2000 Jun; 14(6):775-82. PubMed ID: 10848662
[TBL] [Abstract][Full Text] [Related]
10. New developments in the treatment of irritable bowel syndrome.
De Schryver AM; Samsom M
Scand J Gastroenterol Suppl; 2000; (232):38-42. PubMed ID: 11232489
[TBL] [Abstract][Full Text] [Related]
11. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome.
Delvaux M; Louvel D; Mamet JP; Campos-Oriola R; Frexinos J
Aliment Pharmacol Ther; 1998 Sep; 12(9):849-55. PubMed ID: 9768527
[TBL] [Abstract][Full Text] [Related]
12. Reduction of colonic motility by intravenous nicardipine in irritable bowel syndrome.
Prior A; Harris SR; Whorwell PJ
Gut; 1987 Dec; 28(12):1609-12. PubMed ID: 3428688
[TBL] [Abstract][Full Text] [Related]
13. 5-HT4 receptor antagonism in irritable bowel syndrome: effect of SB-207266-A on rectal sensitivity and small bowel transit.
Houghton LA; Jackson NA; Whorwell PJ; Cooper SM
Aliment Pharmacol Ther; 1999 Nov; 13(11):1437-44. PubMed ID: 10571599
[TBL] [Abstract][Full Text] [Related]
14. Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia?
Maxton DG; Morris J; Whorwell PJ
Aliment Pharmacol Ther; 1996 Aug; 10(4):595-9. PubMed ID: 8853764
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the interaction of zamifenacin at muscarinic receptors in vitro.
Watson N; Reddy H; Stefanich E; Eglen RM
Eur J Pharmacol; 1995 Oct; 285(2):135-42. PubMed ID: 8566131
[TBL] [Abstract][Full Text] [Related]
16. Colonic myoelectrical activity in irritable-bowel syndrome. Effect of eating and anticholinergics.
Sullivan MA; Cohen S; Snape WJ
N Engl J Med; 1978 Apr; 298(16):878-83. PubMed ID: 345122
[TBL] [Abstract][Full Text] [Related]
17. Reduction by cimetropium bromide of the colonic motor response to eating in patients with the irritable bowel syndrome.
Lanfranchi GA; Bazzocchi G; Campieri M; Brignola C; Fois F; Imbimbo BP
Eur J Clin Pharmacol; 1988; 33(6):571-5. PubMed ID: 3366160
[TBL] [Abstract][Full Text] [Related]
18. Cholecystokinin's role in regulation of colonic motility in health and in irritable bowel syndrome.
Niederau C; Faber S; Karaus M
Gastroenterology; 1992 Jun; 102(6):1889-98. PubMed ID: 1587408
[TBL] [Abstract][Full Text] [Related]
19. Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome.
Thumshirn M; Coulie B; Camilleri M; Zinsmeister AR; Burton DD; Van Dyke C
Aliment Pharmacol Ther; 2000 Jul; 14(7):869-78. PubMed ID: 10886042
[TBL] [Abstract][Full Text] [Related]
20. Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome.
Noor N; Small PK; Loudon MA; Hau C; Campbell FC
Scand J Gastroenterol; 1998 Jun; 33(6):605-11. PubMed ID: 9669632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
